Sun Pharma up 2% as arm gets relief by US court in patent infringement case

On a year-to-date (YTD) basis, Sun Pharma stock has underperformed the Nifty Pharma index by declining around 28 per cent.

Shares of Sun Pharma climbed as much as 2.41 per cent in the morning trade on Thursday after DUSA Pharmaceuticals, an arm of of the Mumbai-based pharma major, received relief from a US court in a patent infringement case. 

Massachusetts-based DUSA has been granted preliminary injunctive relief by a federal district court prohibiting defendants Biofrontera Inc, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AGf from using its confidential and proprietary trade secret information, the company said in a regulatory filing.

Earlier this year, DUSA, which is wholly-owned by Sun Pharma, filed a lawsuit against the Biofrontera defendants in the